Form 4: AnaptysBio Chief Medical Officer Paul F. Lizzul Reports Stock Transactions
SEC Form 4 Filing
Chief Medical Officer of AnaptysBio, Paul F. Lizzul, reports acquisition and disposal of company stock to cover tax obligations.
Summary
- On September 14, 2024, Paul F. Lizzul, Chief Medical Officer of AnaptysBio, acquired 6,000 shares of common stock through the vesting of restricted stock units (RSUs).
- On September 16, 2024, Lizzul sold 2,220 shares of common stock at a price of $38.93 per share.
- The sale was to cover tax withholding obligations related to the vesting of the RSUs and was not a discretionary transaction.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Key Dates
| Date | Description |
|---|---|
| 09/14/2023 | 50% of the total restricted stock units vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| 09/14/2024 | 50% of the total restricted stock units vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| 09/14/2024 | Acquisition of 6,000 shares of common stock through RSU vesting. |
| 09/16/2024 | Sale of 2,220 shares of common stock at $38.93 per share. |
| 09/17/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.